Cargando…
Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
The urgent need for novel and effective drugs against the SARS-CoV-2 coronavirus pandemic has stimulated research worldwide. The Papain-like protease (PLpro), which is essential for viral replication, shares a similar active site structural architecture to other cysteine proteases. Here, we have use...
Autores principales: | Sivakumar, Dakshinamurthy, Stein, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227062/ https://www.ncbi.nlm.nih.gov/pubmed/34071582 http://dx.doi.org/10.3390/biom11060802 |
Ejemplares similares
-
Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020) -
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022) -
Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
por: Hognon, Cécilia, et al.
Publicado: (2022) -
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022) -
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
por: Sanders, Brian C., et al.
Publicado: (2023)